870706-48-2

Upstream product

• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 870706-47-1 4-chloro-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 717899-32-6 1-[3-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-3-(4-chloro-phenyl)-urea 
• 1432478-56-2 C₁₆H₁₇N₅O 
• 1432478-55-1 C₁₆H₁₅N₅O₃ 
• 717899-13-3 1-[3-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-3-(2-fluoro-5-methyl-phenyl)-urea 
• 717899-12-2 1-[3-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-3-(2-methoxy-5-methyl-phenyl)-urea 
• 1080829-28-2 N-[3-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-chloro-benzenesulfonamide 
• 1027488-77-2 N-[3-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-2,4-dichloro-benzenesulfonamide 

Relevant academic research and scientific papers

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated. More particularly, the present invention relates to a compound of Formula I.

CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone derivatives. Specifically, the invention is directed to compounds according to Formula X: wherein R41, R42, R43, R44, R45, R46, and R47 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt- Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, myocardial infarction, neurodegeneration, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias, more specifically cancers of the breast, colon, pancreas and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors

The synthesis and biological evaluation of novel Tie-2 kinase inhibitors are presented. Based on the pyrrolopyrimidine chemotype, several new series are described, including the benzimidazole series by linking a benzimidazole to the C5-position of the 4-a

PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT

The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof, wherein L, R', R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and to methods of treating abnormal cell growth, such as cancer in a mammal by administering the compounds of formula (I).